Figueiredo Ricardo R, Penido Norma de O, de Azevedo Andréia A, de Oliveira Patrícia M, de Siqueira Adriana G, Figueiredo Guilherme de M R, Schlee Winfried, Langguth Berthold
Faculdade de Medicina, Centro Universitário de Valença, Valença, Brazil.
Departamento de Otorrinolaringologia e Cirurgia de Cabeça e Pescoço, Universidade Federal de São Paulo, São Paulo, Brazil.
Front Neurol. 2022 Sep 9;13:974179. doi: 10.3389/fneur.2022.974179. eCollection 2022.
COVID-19 is a respiratory disease caused by the new coronavirus SARS-CoV-2, for which the first cases were reported in China, by December 2019. The spectrum of clinical presentations is wide, ranging from asymptomatic cases to a severe acute respiratory syndrome, sometimes with multiple systems involvement. Viral infections, including those related to respiratory virus, may cause hearing loss and, by extent, considering its pathophysiology, tinnitus. A systematic review on inner ear related symptoms in patients with COVID-19 reported 4.5% occurrence rate of tinnitus, with high variance of prevalence between the studies. Our aim is to further explore the relationship between COVID-19 and tinnitus. For this purpose we analyzed a sample of people who had suffered from a COVID-19 infection in the city of Volta Redonda, Brazil. In detail, we compared those with new onset tinnitus during or after the COVID-19 infection with those without tinnitus and those with tinnitus onset before the COVID-19 infection.
Fifty-seven patients over 18 years old and previously diagnosed with COVID-19 confirmed by a RT-PCR test were included. Patients were subdivided in three groups: no tinnitus (NT), tinnitus that already existed before COVID-19 (chronic tinnitus, CT) and tinnitus that arose during or after COVID-19 (post-COVID-19 tinnitus, PCT). Data concerning COVID-19 symptoms, drugs prescribed for COVID-19, tinnitus characteristics, comorbidities and other otological symptoms were collected. For all the patients, tonal audiometry and otoacoustic emissions were performed. Tinnitus patients fulfilled the Tinnitus Handicap Inventory (THI) and visual-analog scales (VAS) for loudness and distress. Patients with CT answered a simple question about the worsening of their tinnitus after COVID-19.
PCT was reported by 19.3% of the patients, while 22.8% reported CT. No statistical difference was found between CT and PCT concerning hearing function, tinnitus characteristics and tinnitus distress. There was also no statistically significant difference between PCT and NT with respect to COVID-19 symptoms and pharmacological COVID-19 treatment. Patients with CT reported worsening of their tinnitus after COVID-19.
As with other viral infections, inner ear symptoms may be associated with COVID-19. In our sample patients with tinnitus onset before COVID-19 and those with tinnitus onset during or after COVID-19 did not differ significantly in their clinical characteristics and their hearing function, suggesting that tinnitus occurring in the context of a COVID-19 infection is not related to a unique pathophysiological mechanism. The comparison of COVID-19 patients, who developed tinnitus with those who did not develop tinnitus did not reveal any differences in COVID-19 symptoms or COVID-19 treatment. Thus, there was no hint, that a specific expression of COVID-19 is closely related to post COVID-19 tinnitus onset. Although some drugs used to treat tinnitus are known to damage the inner ear cells (especially hydroxychloroquine), we did not see any relationship between the intake of these drugs and tinnitus onset, eventually due to the short prescription time and low doses. Among those patients who had tinnitus before COVID-19 30,8% reported worsening after COVID-19. Overall, tinnitus emerging in the context of a COVID-19 infection seems not to differ from tinnitus unrelated to COVID-19. For further exploring the relationship of tinnitus and COVID-19, large population based studies are warranted.
新型冠状病毒肺炎(COVID-19)是由新型冠状病毒SARS-CoV-2引起的一种呼吸道疾病,2019年12月在中国报告了首例病例。其临床表现范围广泛,从无症状病例到严重急性呼吸综合征,有时还会累及多个系统。病毒感染,包括与呼吸道病毒相关的感染,可能导致听力损失,从病理生理学角度考虑,还可能导致耳鸣。一项关于COVID-19患者内耳相关症状的系统评价报告称,耳鸣的发生率为4.5%,各研究之间的患病率差异很大。我们的目的是进一步探讨COVID-19与耳鸣之间的关系。为此我们分析了巴西福尔塔雷东达市感染过COVID-19的人群样本。具体而言,我们将COVID-19感染期间或之后出现新发耳鸣的患者与无耳鸣的患者以及COVID-19感染之前就已出现耳鸣的患者进行了比较。
纳入57例年龄在18岁以上且先前经逆转录聚合酶链反应(RT-PCR)检测确诊为COVID-19的患者。患者被分为三组:无耳鸣组(NT)、COVID-19之前就已存在的耳鸣组(慢性耳鸣,CT)和COVID-19期间或之后出现的耳鸣组(COVID-19后耳鸣,PCT)。收集有关COVID-19症状、针对COVID-19开具的药物、耳鸣特征、合并症及其他耳科症状的数据。对所有患者进行纯音听力测试和耳声发射测试。耳鸣患者完成耳鸣障碍量表(THI)以及关于响度和苦恼的视觉模拟量表(VAS)。CT组患者回答了一个关于COVID-19后其耳鸣是否加重的简单问题。
19.3%的患者报告有PCT,而22.8%的患者报告有CT。在听力功能、耳鸣特征和耳鸣苦恼方面,CT组和PCT组之间未发现统计学差异。在COVID-19症状和COVID-19药物治疗方面,PCT组和NT组之间也没有统计学上的显著差异。CT组患者报告COVID-19后其耳鸣加重。
与其他病毒感染一样,内耳症状可能与COVID-19有关。在我们的样本中,COVID-19之前就已出现耳鸣的患者与COVID-19期间或之后出现耳鸣的患者在临床特征和听力功能方面没有显著差异,这表明在COVID-19感染背景下出现的耳鸣与独特的病理生理机制无关。将出现耳鸣的COVID-19患者与未出现耳鸣的患者进行比较,未发现COVID-19症状或COVID-19治疗方面有任何差异。因此,没有迹象表明COVID-19的特定表现与COVID-19后耳鸣的发生密切相关。尽管已知一些用于治疗耳鸣的药物会损害内耳细胞(尤其是羟氯喹),但我们未发现这些药物的摄入与耳鸣发生之间存在任何关系,最终可能是由于处方时间短且剂量低。在COVID-19之前就有耳鸣的患者中,30.8%报告COVID-19后耳鸣加重。总体而言,在COVID-19感染背景下出现的耳鸣似乎与与COVID-19无关的耳鸣没有区别。为进一步探讨耳鸣与COVID-19的关系,有必要开展基于大量人群的研究。